Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Meta’s Muse AI agent aims to automate users’ digital lives, but internal tests reportedly uncovered privacy risks and reliability issues.
HealthEx launched a connector enabling U.S. consumers to link their medical records to Muse, Meta's new personal AI agent. The integration allows Muse to provide personalized health guidance, track follow-ups, and help users manage health goals by accessing their complete health history through HealthEx's secure platform, with full user control over data sharing.
Vistra's stock has declined nearly 30% from its September 2025 record high of $217.02 to $154, shedding its 'AI premium' due to battery storage facility shutdowns and regulatory challenges from PJM Interconnection. Despite near-term headwinds, analysts expect strong 2026 growth (29% revenue, quadrupling EPS) driven by data center electricity demand. Trading at 15x 2027 earnings with a 0.6% dividend yield, the stock represents a buying opportunity for long-term investors confident in continued AI infrastructure expansion.
Broadcom and Marvell are leading players in the custom AI chip market, with Broadcom expected to control 60% market share by 2027 versus Marvell's 20-25%. Broadcom demonstrates significantly faster growth with AI chip revenue projected to reach $230 billion by fiscal 2028 and EPS exceeding $30, compared to Marvell's more modest 45-50% annual growth guidance. Despite Marvell's 163% stock gain in 2026, Broadcom's cheaper valuation combined with superior growth trajectory makes it the more attractive investment opportunity.